3 results
1. To investigate whether the TIMELY intervention is superior to usual care in terms of A) reducing the CoroPredict risk score (indicating risk of 10-year mortality: primary biomedical outcome) from baseline to six months; andB) increasing…
To demonstrate that lorlatinib as a single agent (Arm A) is superior to crizotinib alone (Arm B) in prolonging Progression-Free Survival (PFS) in advanced ALK-positive NSCLC participants who are treatment naive.
The aim of this study is to compare the 3D designed prosthesis with the conventional made prosthesis.Study questions:- How is the 3D designed prosthesis compared to the conventional prosthesis? The final chosen workflow and settings will be applied…